drugset / Trial / NCT02476890
Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014)
Phase 2
Completed
36 enrolled
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
RandomizedCrossoverTriple-blindTreatment
Summary
The primary objective of this study was to assess the effect of a single dose of gefapixant 100 mg on cough reflex sensitivity to various challenge agents (capsaicin, citric acid, adenosine triphosphate \[ATP\], and distilled water) in healthy and chronic cough participants.
Timeline
- Start
- 2015-10-28
- Primary completion
- 2016-10-20
- Completion
- 2016-10-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefapixant | Small molecule | 100 mg | Oral |